Oryzon Genomics Management
Management criteria checks 2/4
Oryzon Genomics' CEO is Carlos Manuel Arjol, appointed in Jan 2000, has a tenure of 25.33 years. total yearly compensation is €477.00K, comprised of 68.1% salary and 31.9% bonuses, including company stock and options. directly owns 3.75% of the company’s shares, worth €7.72M. The average tenure of the management team and the board of directors is 5.6 years and 1.3 years respectively.
Key information
Carlos Manuel Arjol
Chief executive officer
€477.0k
Total compensation
| CEO salary percentage | 68.1% |
| CEO tenure | 25.3yrs |
| CEO ownership | 3.7% |
| Management average tenure | 5.6yrs |
| Board average tenure | 1.3yrs |
Recent management updates
Recent updates
Insufficient Growth At Oryzon Genomics S.A. (BME:ORY) Hampers Share Price
Feb 13
Growth Investors: Industry Analysts Just Upgraded Their Oryzon Genomics S.A. (BME:ORY) Revenue Forecasts By 54%
Oct 03Oryzon Genomics S.A. (BME:ORY) Screens Well But There Might Be A Catch
Jun 09Is Oryzon Genomics (BME:ORY) Using Too Much Debt?
Apr 04Industry Analysts Just Made A Dazzling Upgrade To Their Oryzon Genomics S.A. (BME:ORY) Revenue Forecasts
Jul 24Is Oryzon Genomics (BME:ORY) Weighed On By Its Debt Load?
May 01Oryzon Genomics (BME:ORY) Has Debt But No Earnings; Should You Worry?
Feb 26If You Had Bought Oryzon Genomics (BME:ORY) Shares A Year Ago You'd Have Earned 18% Returns
Jan 04
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2024 | €477k | €325k | -€4m |
| Sep 30 2024 | n/a | n/a | -€4m |
| Jun 30 2024 | n/a | n/a | -€4m |
| Mar 31 2024 | n/a | n/a | -€3m |
| Dec 31 2023 | €456k | €313k | -€3m |
| Sep 30 2023 | n/a | n/a | -€4m |
| Jun 30 2023 | n/a | n/a | -€4m |
| Mar 31 2023 | n/a | n/a | -€4m |
| Dec 31 2022 | €421k | n/a | -€4m |
Compensation vs Market: Carlos Manuel's total compensation ($USD539.29K) is about average for companies of similar size in the Spanish market ($USD536.30K).
Compensation vs Earnings: Carlos Manuel's compensation has increased whilst the company is unprofitable.
CEO
Carlos Manuel Arjol
25.3yrs
Tenure
€477,000
Compensation
Dr. Carlos Manuel Buesa Arjol Co-Founded Oryzon Genomics S.A. in 2000 and has been its Chairman and Chief Executive Officer since 2001 and serves as its President and served as its Member of Financial Advi...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder | 25.3yrs | €477.00k | 3.75% € 7.7m | |
| COO & CFO | 4.9yrs | no data | no data | |
| Scientific Director | 4.3yrs | no data | no data | |
| Head of Internal Audit & Compliance | no data | no data | no data | |
| Secretary | no data | no data | no data | |
| Director of Business Development | no data | no data | no data | |
| Director of Industrial Property | no data | no data | no data | |
| Medical Director of SNC | 6.3yrs | no data | no data | |
| Director of Clinical Operations | no data | no data | no data |
5.6yrs
Average Tenure
Experienced Management: ORY's management team is seasoned and experienced (5.6 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder | 24.3yrs | €477.00k | 3.75% € 7.7m | |
| Independent Director | less than a year | no data | no data | |
| Member of Clinical Advisory Board - Oncology | 7.3yrs | no data | no data | |
| Lead Independent Director | 5yrs | €65.00k | no data | |
| Member of Clinical Advisory Board - Oncology | 1.3yrs | no data | no data | |
| Member of Clinical Advisory Board - Oncology | no data | no data | no data | |
| Independent Director | less than a year | no data | no data | |
| Member of Clinical Advisory Board - Oncology | no data | no data | no data | |
| Independent Director | less than a year | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Clinical Advisory Board - Oncology | 1.3yrs | no data | no data | |
| Independent Director | less than a year | no data | no data |
1.3yrs
Average Tenure
66yo
Average Age
Experienced Board: ORY's board of directors are not considered experienced ( 1.3 years average tenure), which suggests a new board.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/02 19:53 |
| End of Day Share Price | 2025/05/02 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Oryzon Genomics S.A. is covered by 5 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jyoti Prakash | Edison Investment Research |
| Arron Aatkar | Edison Investment Research |
| Joaquin Garcia-Quiros | JB Capital Markets |